title: Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why?
abstract: When cells are stimulated with the cytokines IFN-gamma or TNF-alpha, the synthesis of three proteasome subunits LMP2 (beta1i), LMP7 (beta5i), and MECL-1 (beta2i) is induced. These subunits replace the three subunits delta (beta1), MB1 (beta5), and Z (beta2), which bear the catalytically active sites of the proteasome, during proteasome neosynthesis. The cytokine-induced exchanges of three active site subunits of a complex protease is unprecedented in biology and one may expect a strong functional driving force for this system to evolve. These cytokine-induced replacements of proteasome subunits are believed to favour the production of peptide ligands of major histocompatibility complex (MHC) class I molecules for the stimulation of cytotoxic T cells. Although the peptide production by constitutive proteasomes is able to maintain peptide-dependent MHC class I cell surface expression in the absence of LMP2 and LMP7, these subunits were recently shown to be pivotal for the generation or destruction of several unique epitopes. In this review we discuss the recent data on LMP2/LMP7/MECL-1-dependent epitope generation and the functions of each of these subunit exchanges. We propose that these subunit exchanges have evolved not only to optimize class I peptide loading but also to generate LMP2/LMP7/MECL-1-dependent epitopes in inflammatory sites which are not proteolytically generated in uninflamed tissues. This difference in epitope generation may serve to better stimulate T cells in the sites of an ongoing immune response and to avoid autoimmunity in uninflamed tissues.
authors: Research Department, Cantonal Hospital St. Gall, 9007, St. Gallen, Switzerland. lfal@msl.kssg.ch
authors: M
authors: M
authors: Groettrup
authors: S
authors: S
authors: Khan
authors: K
authors: K
authors: Schwarz
authors: G
authors: G
authors: Schmidtke
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D001665:Binding Sites / Q000502:physiology; D003546:Cysteine Endopeptidases / Q000096:biosynthesis* / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000494:pharmacology; D005805:Genes, MHC Class I; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology* / Q000494:pharmacology; D009097:Multienzyme Complexes / Q000096:biosynthesis*; D010447:Peptide Hydrolases / Q000096:biosynthesis; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex; D014176:Protein Biosynthesis; D021122:Protein Subunits; D011506:Proteins / Q000187:drug effects; D013601:T-Lymphocytes / Q000201:enzymology / Q000276:immunology
chemical_list: D016207:Cytokines; D009097:Multienzyme Complexes; D010455:Peptides; D021122:Protein Subunits; D011506:Proteins; C071313:LMP-2 protein; D007371:Interferon-gamma; D010447:Peptide Hydrolases; D003546:Cysteine Endopeptidases; C098949:proteasome subunit Z; C077436:LMP7 protein; C098948:PSMB10 protein, human; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease